24 April 2018 - Deborah Wilkes
Archived
Blackmores has agreed to acquire an Australian tablet and softgel capsule manufacturing facility from Catalent for around AUD43.2 million (USD32.7 million). The Australian natural health specialist said the transaction would give it "increased agility to respond to changing marketing conditions" and "future-proof its Asian business".
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.